<DOC>
	<DOCNO>NCT00792805</DOCNO>
	<brief_summary>This study evaluate efficacy safety two dos indacaterol adult age 40 chronic obstructive pulmonary disease ( COPD ) China two country .</brief_summary>
	<brief_title>Efficacy Safety Indacaterol Adults ( 40 Years Above ) With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Adults age ≥ 40 year Diagnosis chronic obstructive pulmonary disease ( COPD ) ( moderate severe classify Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines , 2007 ) : 1 . Smoking history least 10 pack year 2 . Postbronchodilator force expiratory volume 1 second ( FEV1 ) &lt; 80 % ≥ 30 % predict normal value 3 . Postbronchodilator FEV1/FVC ( force vital capacity ) &lt; 70 % Patients receive systemic corticosteroid COPD exacerbation 6 week prior screen runin period Patients require longterm oxygen therapy ( &gt; 15 hour day ) chronic hypoxemia Patients respiratory tract infection within 6 week prior screen Patients concomitant pulmonary disease Patients history asthma Patients diabetes Type I uncontrolled diabetes Type II Any patient lung cancer history lung cancer Any patient active cancer history cancer le 5 year diseasefree survival time Patients history long QT syndrome whose QTc interval ( Bazett 's ) measure screen prolonged Patients vaccinate live attenuate vaccine within 30 day prior screen runin period Patients unable successfully use dry powder inhaler device perform spirometry measurements Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>COPD</keyword>
	<keyword>indacaterol</keyword>
	<keyword>long-acting β2-agonist</keyword>
	<keyword>adult</keyword>
</DOC>